Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite substantial progress in the treatment pediatric acute leukemia a significant number of children will experience primary or secondary resistance to the treatment. In other words it will be not possible to achieve remission using standard chemotherapy (primary resistance) or the patients will develop chemotherapy resistant relapse (secondary resistance). Children failing to achieve remission or children relapsing after previous allogeneic stem cell transplantation have short life expectancy and palliative treatment still remains the most reasonable option as the escalation of conventional chemotherapy is not longer effective.

The role of Graft versus Leukemia effect was postulated as one of the mechanisms contributing to the leukemia control/eradication after transplantation of hematopoietic stem cells.

In this study the investigators combine intensified multiagent Clofarabine containing chemotherapy with post-induction treatment intensification using reduced intensity conditioning followed by haploidentical hematopoietic stem cell transplantation. Introducing a new drug to the treatment of resistant leukemia the investigators want to achieve a response which allows us to proceed to immediate haploidentical transplantation. Using a haploidentical donor the investigators can avoid time consuming search for an unrelated donor and perform the transplantation at the optimal time-point. Combating therapy resistant leukemia the investigators would like to evoke and utilize potential Graft-versus-Leukemia effect which is much more pronounced in the haploidentical setting, as it is well documented that allogeneic transplantation with a matched donor is not effective in resistant disease. The use of best KIR mismatch donor and post-transplant donor lymphocyte infusion will be implemented in order to develop/intensify graft versus leukemia effect.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

NCT01423747

Lymphoblastic Leukemia, Acute, Childhood;

UNKNOWN PHASE3

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

NCT00824135

Hematologic Malignancies

COMPLETED PHASE1

Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies

NCT00145613

Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia (AML) Secondary AML +7 more

COMPLETED PHASE2

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

NCT00423514

Graft Versus Host Disease Leukemia Myelodysplastic Syndromes

COMPLETED PHASE1/PHASE2

HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors

NCT01509300

Acute Leukemia Myelodysplastic Syndrome Solid Tumors

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Remission induction and haplo-SCT

Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.

Group Type EXPERIMENTAL

Clofarabine for remission induction

Intervention Type DRUG

Etoposide for remission induction

Intervention Type DRUG

Cyclophosphamide for remission induction

Intervention Type DRUG

Clofarabine in conditioning before transplantation

Intervention Type DRUG

Thiotepa in conditioning before transplantation

Intervention Type DRUG

Melfalan in conditioning before transplantation

Intervention Type DRUG

Haploidentical transplantation of T-cell depleted graft

Intervention Type PROCEDURE

Donor lymphocyte infusion

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clofarabine for remission induction

Intervention Type DRUG

Etoposide for remission induction

Intervention Type DRUG

Cyclophosphamide for remission induction

Intervention Type DRUG

Clofarabine in conditioning before transplantation

Intervention Type DRUG

Thiotepa in conditioning before transplantation

Intervention Type DRUG

Melfalan in conditioning before transplantation

Intervention Type DRUG

Haploidentical transplantation of T-cell depleted graft

Intervention Type PROCEDURE

Donor lymphocyte infusion

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Target population

1. Refractory acute lymphoblastic leukemia

* Chemoresistant isolated or combined bone marrow relapse

* Relapse after during/after conventional treatment
* Relapse ≥6 months after allogeneic stem cell transplantation
* Primary induction failure
* Isolated extramedullary relapse after previous HSCT (\>6 months)
2. Refractory acute myeloblastic leukemia including sAML

* Chemoresistant relapse

* Relapse after during/after conventional treatment
* Relapse ≥6 months after allogeneic stem cell transplantation
* Primary induction failure

1. Age ≥ 1 and ≤21 years
2. Patients with previous HCST ≥ 6 m
3. Provide signed written informed consent patients', and patients' parents /guardians

* Older children should be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent as well.
4. Cardiac output SF ≥25%
5. Have adequate renal and hepatic functions as indicated by the following laboratory values:

* Calculated creatinine clearance ≥90 ml/min/1.73 m2
* Serum bilirubin ≤1.5 X upper limit of normal (ULN)
* Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 X ULN
* Alkaline phosphatase ≤ 2.5 X ULN
6. Performance score of ≥70% (Lansky or Karnofsky)
7. A suitable haploidentical family member available for stem cell donation, \> 18 years of age, fulfilling institutional criteria for blood and marrow donation.
8. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

1. Cardiac output SF ≥25%
2. Have adequate renal and hepatic functions as indicated by the following laboratory values:

* Calculated creatinine clearance ≥90 ml/min/1.73 m2
* Serum bilirubin ≤1.5 X upper limit of normal (ULN)
* Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 X ULN
* Alkaline phosphatase ≤ 2.5 X ULN
3. Performance score of ≥70% (Lansky or Karnofsky)
4. A suitable haploidentical family member available for stem cell donation, \> 18 years of age, fulfilling institutional criteria for blood and marrow donation.
5. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
6. Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
7. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

Exclusion Criteria

1. Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
2. Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea.

The patient must have recovered from all acute toxicities from any previous therapy.
3. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
4. Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
5. Pregnant or lactating patients.
6. Any significant concurrent malignant disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

Minimum Eligible Age

1 Year

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No